^
    8d
    EZH2 Expression Is Associated With Sensitivity to Inhibitors and Promotes Malignancy in Endometrial Cancer Cells. (PubMed, Anticancer Res)
    EZH2 plays a crucial role in promoting malignant phenotypes in EC, and its expression level correlates with cellular sensitivity to EZH2 inhibitors. These findings suggest that EZH2 could serve as a valuable therapeutic target and predictive biomarker for personalized medicine in EC.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    Tazverik (tazemetostat) • GSK2816126 • EPZ005687 • lirametostat (CPI-1205)
    4ms
    ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=175, Completed, Constellation Pharmaceuticals | Phase classification: P1b/2 --> P1/2 | Active, not recruiting --> Completed
    Trial completion • Phase classification
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tybost (cobicistat) • lirametostat (CPI-1205)
    4years
    EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine. (PubMed, Sci Rep)
    The EZH2 inhibitor GSK126 also repressed proliferation of CNDT2.5 cells. Exposure of GOT1 three-dimensional cell spheroids to CPI-1205 or metformin arrested cell proliferation and decreased spheroid size. These novel findings support a possible role of EZH2 as a candidate oncogene in SI-NETs, and suggest that CPI-1205 and metformin should be further evaluated as therapeutic options for patients with SI-NETs.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    metformin • GSK2816126 • lirametostat (CPI-1205)
    5years
    ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=24, Completed, Constellation Pharmaceuticals | Active, not recruiting --> Completed | Phase classification: P1/2 --> P1
    Clinical • Trial completion • Phase classification • Pan tumor
    |
    PD-L1 (Programmed death ligand 1)
    |
    Yervoy (ipilimumab) • lirametostat (CPI-1205)